Humana lowered its full-year 2026 GAAP EPS guidance to at least $6.52 from at least $8.36, even as it reported second-quarter revenue of $40,867 million and net income of $694 million. The company also confirmed completion of a $276.13 million share repurchase program and announced two new board appointments, Paul Smith and Frederick Crawford. The guidance cut signals a more cautious profitability outlook amid medical cost and Stars-related headwinds, while the quarterly beat and stable revenue trends indicate the core Medicare Advantage and CenterWell franchise remains intact.
Humana IncCompany cut 2026 EPS guidance to at least $6.52 from $8.36, signaling cautious profitability outlook.
